226 related articles for article (PubMed ID: 17267922)
21. Regulatory watch: Impact of scientific advice from the European Medicines Agency.
Hofer MP; Jakobsson C; Zafiropoulos N; Vamvakas S; Vetter T; Regnstrom J; Hemmings RJ
Nat Rev Drug Discov; 2015 May; 14(5):302-3. PubMed ID: 25881970
[No Abstract] [Full Text] [Related]
22. The regulatory system in europe with special emphasis on allergen products.
Lorenz AR; Luttkopf D; Seitz R; Vieths S
Int Arch Allergy Immunol; 2008; 147(4):263-75. PubMed ID: 18648190
[TBL] [Abstract][Full Text] [Related]
23. [Procedure for the marketing authorization of an antibacterial agent].
López Navas A; García-Escribano Ráez N; Flores Juberías Á; Suárez Gea ML
Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):529-32. PubMed ID: 25124488
[TBL] [Abstract][Full Text] [Related]
24. The licensing of medicines in the UK.
Drug Ther Bull; 2009 Apr; 47(4):45-8. PubMed ID: 19357299
[TBL] [Abstract][Full Text] [Related]
25. The impact of European regulatory policies on psychotropic drug prescribing patterns.
Garattini S; Bertele' V
Int Rev Psychiatry; 2005 Jun; 17(3):199-204. PubMed ID: 16194791
[TBL] [Abstract][Full Text] [Related]
26. A critique to the European regulatory system.
Bertele' V; Li Bassi L
J Ambul Care Manage; 2004; 27(2):98-104. PubMed ID: 15069986
[TBL] [Abstract][Full Text] [Related]
27. [Europe and medicines: role of the EMEA].
Sauer F
Ann Pharm Fr; 2000 Jul; 58(4):278-85. PubMed ID: 10915977
[TBL] [Abstract][Full Text] [Related]
28. Are women appropriately represented and assessed in clinical trials submitted for marketing authorization? A review of the database of the European Medicines Agency.
Müllner M; Vamvakas S; Rietschel M; van Zwieten-Boot BJ
Int J Clin Pharmacol Ther; 2007 Sep; 45(9):477-84. PubMed ID: 17907590
[TBL] [Abstract][Full Text] [Related]
29. [Drug monitoring and regulatory aspects of psychotropic drugs in childhood and adolescence].
Hebebrand J; Gerlach M
Z Kinder Jugendpsychiatr Psychother; 2009 Jul; 37(4):280-2. PubMed ID: 20306786
[No Abstract] [Full Text] [Related]
30. Drug evaluation in children 10years after the European pediatric regulation current challenges and perspectives.
Élie V; Leroux S; Kaguelidou F; Jacqz-Aigrain E
Therapie; 2018 Apr; 73(2):113-117. PubMed ID: 29580612
[TBL] [Abstract][Full Text] [Related]
31. [Biosimilars: regulatory status for approval].
Herrero Ambrosio A
Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
[TBL] [Abstract][Full Text] [Related]
32. The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports.
Erhel F; Scanff A; Naudet F
Epidemiol Psychiatr Sci; 2020 Apr; 29():e120. PubMed ID: 32336312
[TBL] [Abstract][Full Text] [Related]
33. [Off-label use of drugs in psychiatry and neurology].
Wallesch CW
Fortschr Neurol Psychiatr; 2004 May; 72(5):243-4. PubMed ID: 15136944
[No Abstract] [Full Text] [Related]
34. Overview of the European regulatory approval system.
Pignatti F; Boone H; Moulon I
J Ambul Care Manage; 2004; 27(2):89-97. PubMed ID: 15069985
[TBL] [Abstract][Full Text] [Related]
35. The US and European regulatory systems: a comparison.
Redmond K
J Ambul Care Manage; 2004; 27(2):105-14. PubMed ID: 15069987
[TBL] [Abstract][Full Text] [Related]
36. The European Medicines Agency facilitates access to medicines in low- and middle-income countries.
Cavaller Bellaubi M; Harvey Allchurch M; Lagalice C; Saint-Raymond A
Expert Rev Clin Pharmacol; 2020 Mar; 13(3):321-325. PubMed ID: 32053756
[No Abstract] [Full Text] [Related]
37. European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK.
Reichert JM; Beck A; Iyer H
MAbs; 2009; 1(5):394-416. PubMed ID: 20065643
[TBL] [Abstract][Full Text] [Related]
38. CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation?
Barbui C; Cipriani A; Lintas C; Bertelé V; Garattini S
Psychopharmacology (Berl); 2007 Feb; 190(2):265-8. PubMed ID: 17119928
[No Abstract] [Full Text] [Related]
39. Pediatric psychopharmacological research in the post EU regulation 1901/2006 era.
Schmäl C; Becker K; Berg R; Brünger M; Lehmkuhl G; Oehler KU; Ruppert T; Staudter C; Trott GE; Dittmann RW
Z Kinder Jugendpsychiatr Psychother; 2014 Nov; 42(6):441-9. PubMed ID: 25335522
[TBL] [Abstract][Full Text] [Related]
40. Regulatory meta-analyses for the evaluation of psychotropic medicines.
Barbui C; Purgato M; Ostuzzi G
Lancet Psychiatry; 2017 Sep; 4(9):660-661. PubMed ID: 28853404
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
